BRPI0905847B8 - composição farmacêutica injetável - Google Patents

composição farmacêutica injetável

Info

Publication number
BRPI0905847B8
BRPI0905847B8 BRPI0905847A BRPI0905847A BRPI0905847B8 BR PI0905847 B8 BRPI0905847 B8 BR PI0905847B8 BR PI0905847 A BRPI0905847 A BR PI0905847A BR PI0905847 A BRPI0905847 A BR PI0905847A BR PI0905847 B8 BRPI0905847 B8 BR PI0905847B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
injectable pharmaceutical
chosen
hydrophobic
composition
Prior art date
Application number
BRPI0905847A
Other languages
English (en)
Inventor
Bastiat Guillaume
Leroux Jean-Christophe
Original Assignee
Ethypharm Sa
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa, Univ Montreal filed Critical Ethypharm Sa
Publication of BRPI0905847A2 publication Critical patent/BRPI0905847A2/pt
Publication of BRPI0905847B1 publication Critical patent/BRPI0905847B1/pt
Publication of BRPI0905847B8 publication Critical patent/BRPI0905847B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

composição farmacêutica injetável e processo para preparar a composição a presente invenção trata de uma composição farmacêutica injetável com propriedades geleificantes que contém: - um princípio ativo; um líquido orgânico hidrofóbico e biocompatível, e uma substância organogeleificante, cujas moléculas têm a capacidade de se ligar entre si por meio de ligações de baixa energia, em que a referida substância organogeleificante é escolhida entre os derivados de l-tirosina que correspondem à seguinte fórmula: (i) em que: . r1 é um grupo alquil que contém 1 a 3 átomos de carbono, lineares ou ramificados; e . r2 é um grupo hidrofóbico escolhido entre as cadeias graxas alifáticas saturadas ou insaturadas ou os grupos aril ou arilalquil. seu uso como um vetor para a liberação de princípios ativos, bem como seu processo de preparação.
BRPI0905847A 2008-01-31 2009-01-30 composição farmacêutica injetável BRPI0905847B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2510708P 2008-01-31 2008-01-31
FR0850617 2008-01-31
FR0850617A FR2926996B1 (fr) 2008-01-31 2008-01-31 Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
US61/025,107 2008-01-31
PCT/EP2009/051085 WO2009095485A1 (en) 2008-01-31 2009-01-30 Pharmaceutical composition with gelling properties containing a tyrosine derivative

Publications (3)

Publication Number Publication Date
BRPI0905847A2 BRPI0905847A2 (pt) 2016-08-09
BRPI0905847B1 BRPI0905847B1 (pt) 2019-05-14
BRPI0905847B8 true BRPI0905847B8 (pt) 2021-05-25

Family

ID=39627409

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905847A BRPI0905847B8 (pt) 2008-01-31 2009-01-30 composição farmacêutica injetável

Country Status (10)

Country Link
US (1) US8815944B2 (pt)
EP (1) EP2254550B1 (pt)
JP (1) JP5587211B2 (pt)
CN (1) CN101969924B (pt)
AU (1) AU2009209546B2 (pt)
BR (1) BRPI0905847B8 (pt)
CA (1) CA2713266C (pt)
ES (1) ES2402468T3 (pt)
FR (1) FR2926996B1 (pt)
WO (1) WO2009095485A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CN103221383B (zh) * 2010-08-27 2016-04-20 株式会社新药 促进人源性抗菌肽分泌的新化合物、其制备方法以及含有其作为活性成分的组合物
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
CN102432491B (zh) * 2011-09-08 2013-10-23 西安科技大学 一种基于酪氨酸衍生物的胶凝剂及其应用
CN103980148B (zh) * 2014-01-08 2016-09-14 上海交通大学医学院 硬脂酰氨基酸盐及其制备方法和应用
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA3022218C (en) 2016-05-12 2023-05-09 Rudjer Boskovic Institute Low molecular weight organic gelators of vegetable oil
CA3120396A1 (en) 2018-12-17 2020-06-25 Rudjer Boskovic Institute Composition comprising oxalamide gelators and vegetable oil
EP3955978A1 (en) * 2019-04-18 2022-02-23 DePuy Synthes Products, Inc. Biocompatible organogel matrices for intraoperative preparation of a drug delivery depot
US11613889B2 (en) 2019-10-04 2023-03-28 Innovations & Ideas, Llc Weeping control joint system
CN111545139B (zh) * 2020-06-04 2022-03-11 云南中烟工业有限责任公司 含糖基-酰胺基-芳基-烃基四段式糖基胶凝剂的可逆相变雾化液凝胶及其制备方法和应用
CN113563219B (zh) * 2021-07-29 2023-12-26 沈阳药科大学 L-酪氨酸衍生物和球状介孔二氧化硅纳米粒及其制备方法和应用
CN119139351B (zh) * 2024-11-14 2025-10-10 知佰幸细胞库(浙江)有限公司 一种细胞因子组合物及其在抗衰老虚弱中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969087A (en) * 1974-08-07 1976-07-13 Ajinomoto Co., Ltd. Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
NZ535270A (en) * 2002-03-12 2006-11-30 Univ Montreal Composition having gelling properties for the sustained delivery of bioactive substances
US20050031650A1 (en) 2002-08-26 2005-02-10 Ethypharm Composition with gelling properties for the sustained delivery of bioactive substances
US20070243255A1 (en) * 2004-09-28 2007-10-18 Bing Xu Multifunctional supramolecular hydrogels as biomaterials
CN1868543A (zh) * 2006-06-20 2006-11-29 四川大学 一种生物降解高分子凝胶药物组合物及其制备方法和用途
CN101007170A (zh) * 2007-01-25 2007-08-01 上海交通大学 包虫病药物缓释制剂的制备方法

Also Published As

Publication number Publication date
US8815944B2 (en) 2014-08-26
BRPI0905847A2 (pt) 2016-08-09
CA2713266A1 (en) 2009-08-06
US20110207813A1 (en) 2011-08-25
CA2713266C (en) 2016-02-16
JP5587211B2 (ja) 2014-09-10
WO2009095485A1 (en) 2009-08-06
CN101969924B (zh) 2012-10-24
EP2254550A1 (en) 2010-12-01
BRPI0905847B1 (pt) 2019-05-14
ES2402468T3 (es) 2013-05-06
CN101969924A (zh) 2011-02-09
EP2254550B1 (en) 2013-01-09
JP2011510955A (ja) 2011-04-07
AU2009209546B2 (en) 2013-12-19
FR2926996A1 (fr) 2009-08-07
AU2009209546A1 (en) 2009-08-06
FR2926996B1 (fr) 2013-06-21

Similar Documents

Publication Publication Date Title
BR112012007257A2 (pt) Uso de pelo menos um composto, processo de conservação de uma composição, composto e composições cosmética e dermatológica
ECSP10010129A (es) Inhibidores de quinasas símil polo
BR112013025142A2 (pt) análogos de 3-(1h-benzo{d}imidazol-2-il)-1h-indazol substituído como inibidores da cinase pdk1
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112017003931A2 (pt) composições de surfactante aquoso
BRPI0803024A2 (pt) polìmero em emulsão aquosa, composição aquosa, composição polimérica seca, e, processos para fornecer um polìmero em emulsão aquosa, para fornecer a composição polimérica seca, para engrossar ou modificar a reologia de uma composição aquosa e para formar um agente de raft
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
CU23848B1 (es) Derivados de octahidrofenantreno n(2-metilpiridino-3-il) carboxamida útiles como moduladores de receptor de glucocorticoides
BR112014008934A2 (pt) composição, método de obtenção da composição e formulação fitossanitária que a compreende
BR112012032276A2 (pt) composições de combustível compreendendo derivados de isopreno
BR112013006320A2 (pt) pró-fármacos de ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
CO6410257A2 (es) Herbicidas novedosos
BR112012027530A2 (pt) composição amaciante de tecido
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
BR112012033465A2 (pt) método para preparar um composto
BRPI1016069A8 (pt) Misturas de ésteres e composições compreendendo tais misturas de ésteres
BR112016018065A2 (pt) Composições de surfactante aquoso
AR073808A1 (es) Monomeros de carbamato-metacrilato, sus usos en aplicaciones dentales y procesos para su preparacion.
BRPI0916069C1 (pt) composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição
BR112014031815A2 (pt) composição de combustível renovável e método para uso da mesma
BR112014012458A2 (pt) processo para o preparo de derivados de esterol
BR112015021133B8 (pt) mistura de compostos, processo para produzir uma mistura de compostos e limpar superfícies duras ou fibras, formulação aquosa, e, uso de misturas de compostos
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF